Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria
- First Posted Date
- 2014-04-10
- Last Posted Date
- 2017-07-31
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 4
- Registration Number
- NCT02110147
- Locations
- ๐บ๐ธ
Children's Hospital of Michigan - Specialty Center Detroit, Detroit, Michigan, United States
๐บ๐ธChildren's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination
- Conditions
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Wellstat Therapeutics
- Registration Number
- NCT01432301
Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-05-16
- Last Posted Date
- 2007-08-23
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 90
- Registration Number
- NCT00110864
- Locations
- ๐บ๐ธ
Phoenix Internal Medicine Associates, Waterbury, Connecticut, United States
๐บ๐ธBaptist Diabetes Associates, Miami, Florida, United States
๐บ๐ธCOR Clinical Research, LLC, Oklahoma City, Oklahoma, United States
Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)
- Conditions
- First Posted Date
- 2005-05-16
- Last Posted Date
- 2007-08-23
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 90
- Registration Number
- NCT00110851
- Locations
- ๐บ๐ธ
Endocrine Clinical Research, Winter Park, Florida, United States
๐บ๐ธNeem Research Group, Columbia, South Carolina, United States
๐บ๐ธPhoenix Internal Medicine Associates, Waterbury, Connecticut, United States
Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-06-28
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 250
- Registration Number
- NCT00024427
- Locations
- ๐บ๐ธ
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
๐บ๐ธCancer Center at Greater Baltimore Medical Center, Baltimore, Maryland, United States
๐บ๐ธFox Chase - Temple Cancer Center, Philadelphia, Pennsylvania, United States
Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors
- Conditions
- First Posted Date
- 2002-09-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT00044785
- Locations
- ๐บ๐ธ
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States